Prostate cancer–induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone–tumor microenvironment through Wnt pathway–induced M2 macrophage polarization
Year: 2024
Type: article
Abstract: Immune checkpoint therapy has limited efficacy for patients with bone-metastatic castration-resistant prostate cancer (bmCRPC). To improve immunotherapy for bmCRPC, we aimed to identify the mechanism of bmCRPC-induced changes in the immune microenvironment. Among bmCRPC patients, higher levels of a 32-gene M2-like macrophage signature in bone metastasis samples correlated with shorter overall survival. Immunohistochemistry showed that CD206-positive (CD206 + ) macrophages were enriched in bmCRPC bone biopsy specimens compared with primary tumors or lymph node metastases. In preclinical osteogenic prostate cancer (Pca) xenograft models, CD206 + macrophages were recruited to areas with tumor-induced bone. RNA sequencing (RNAseq) analysis showed higher expression of an M2-like gene signature, with activated canonical and noncanonical Wnt pathways, in tumor-associated macrophages isolated from osteogenic tumors (bone-TAMs) than in TAMs isolated from nonosteogenic tumors (ctrl-TAMs). Mechanistic studies showed that endothelial cells (ECs) that had undergone EC-to-osteoblast (EC-to-OSB) transition, the precursors of tumor-induced OSBs, produced paracrine factors, including Wnts, CXCL14, and lysyl oxidase, which induced M2 polarization and recruited M2-like TAMs to the bone–tumor microenvironment (bone-TME). Bone-TAMs suppressed CD8 + T cells’ proliferation and cytolytic activity, and these effects were partially reversed by treating bone-TAMs with Wnt inhibitors. Genetic or pharmacological inhibition of Pca–induced EC-to-OSB transition reduced the levels of M2-like macrophages in osteogenic tumors. Our study demonstrates that Pca–induced EC-to-OSB transition drives immunosuppression in the bone-TME, suggesting that therapies that reduce Pca–induced bone formation may improve immunotherapeutic outcomes for bmCRPC.
Language: English
Topic: Immune cells in cancer
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Awards: MD Anderson Cancer Center Prostate Cancer SPORE, G4119534169, UTHealth Cancer Genomics Core (UTHealth CGC), G4400572289, G4542989700, G5850682332, G6209763940, G640481018, Endothelial-to-osteoblast transition in prostate cancer bone metastasis, A novel combination therapeutic approach to revitalizing immunotherapy for bone metastatic prostate cancer, G7852774810, G7996396567, Cancer Center Support Grant, Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression
OpenAlex ID: W4401327618
